IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL

被引：0
|
作者：
Doerner, T. [1 ]
Bowman, S. J. [2 ]
Fox, R. [3 ]
Mariette, X. [4 ]
Papas, A. [5 ]
Grader-Beck, T. [6 ]
Fisher, B. A. [2 ]
Barcelos, F. [7 ]
De Vita, S. [8 ]
Schulze-Koops, H. [9 ]
Moots, R. J. [10 ]
Junge, G. [11 ]
Woznicki, J. [12 ]
Sopala, M. [11 ]
Luo, W. [12 ]
Hueber, W. [11 ]
机构：
[1] Charite, Dept Med Rheumatol & Clin Immunol, Berlin, Germany
[2] Univ Hosp Birmingham NHS Fdn Trust, Dept Rheumatol, Birmingham, England
[3] Scripps Mem Hosp & Res Inst, La Jolla, CA USA
[4] Univ Paris Saclay, Paris, France
[5] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA
[6] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA
[7] Inst Portugues Reumatol, Lisbon, Portugal
[8] Univ Hosp Udine, Div Rheumatol, DAME, Udine, Italy
[9] Ludwig Maximilians Univ Munchen, Div Rheumatol & Clin Immunol, Munich, Germany
[10] Aintree Univ Hosp NHS Fdn Trust, Acad Rheumatol Dept, Liverpool, England
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2022年 / 40卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
119
引用
下载
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Tenapanor in Patients With Constipation Predominant Irritable Bowel Syndrome: A 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2B Trial
    Chey, William D.
    Lembo, Anthony
    Phillips, James A.
    Rosenbaum, David P.
    GASTROENTEROLOGY, 2015, 148 (04) : S191 - S192
  • [32] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial
    Wallace, Daniel J.
    Dorner, Thomas
    Pisetsky, David S.
    Sanchez-Guerrero, Jorge
    Patel, Anand C.
    Parsons-Rich, Dana
    Le Bolay, Claire
    Drouin, Elise E.
    Kao, Amy H.
    Guehring, Hans
    Dall'Era, Maria
    ACR OPEN RHEUMATOLOGY, 2023, 5 (01) : 38 - 48
  • [33] TOFACITINIB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A PHASE 2, 16-WEEK, RANDOMISED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
    van der Heijde, D.
    Deodhar, A.
    Wei, J. C.
    Drescher, E.
    Fleishaker, D.
    Hendrikx, T.
    Li, D.
    Menon, S.
    Kanik, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 52 - 53
  • [34] Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
    Fisher, Benjamin A.
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Bootsma, Hendrika
    Ng, Wan-Fai
    van Daele, P. L. A.
    Finzel, Stephanie
    Noaiseh, Ghaith
    Elgueta, Sergio
    Hermann, Josef
    McCoy, Sara S.
    Akpek, Esen
    Bookman, Arthur
    Sopala, Monika
    Montecchi-Palmer, Michela
    Luo, Wen-Lin
    Scheurer, Cornelia
    Hueber, Wolfgang
    LANCET, 2024, 404 (10452): : 540 - 553
  • [35] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
  • [36] Key learnings and the informed design of a randomized, placebo-controlled, dose-ranging phase 2b study to evaluate the efficacy of tezepelumab in moderate-to-severe Atopic Dermatitis
    Komjathy, S.
    Griffiths, J.
    Parnes, J. R.
    ALLERGY, 2020, 75 : 194 - 195
  • [37] Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
    Reilmann, Ralf
    McGarry, Andrew
    Grachev, Igor D.
    Savola, Juha-Matti
    Borowsky, Beth
    Eyal, Eli
    Gross, Nicholas
    Langbehn, Douglas
    Schubert, Robin
    Wickenberg, Anna Teige
    Papapetropoulos, Spyros
    Hayden, Michael
    Squitieri, Ferdinando
    Kieburtz, Karl
    Landwehrmeyer, G. Bernhard
    Agarwal, Pinky
    Anderson, Karen E.
    Aziz, Nasir A.
    Azulay, Jean-Phillippe
    Bachoud-Levi, Anne C.
    Barker, Roger
    Bebak, Agnieszka
    Beuth, Markus
    Biglan, Kevin
    Blin, Stephanie
    Bohlen, Stefan
    Bonelli, Raphael
    Caldwell, Sue
    Calvas, Fabienne
    Carlos, Jonielyn
    Castagliuolo, Simona
    Chong, Terrence
    Chua, Phyllis
    Coleman, Allison
    Corey-Bloom, Jody
    Cousins, Rebecca
    Craufurd, David
    Davison, Jill
    Decorte, Eric
    De Michele, Giuseppe
    Dornhege, Laura
    Feigin, Andrew
    Gallehawk, Stephanie
    Gauteul, Pascale
    Gonzales, Carey
    Griffith, Jane
    Gustov, Alexander
    Guttman, Mark
    Heim, Beatrix
    Heller, Hope
    LANCET NEUROLOGY, 2019, 18 (02): : 165 - 176
  • [38] EFFICACY AND SAFETY OF LY2951742 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY IN PATIENTS WITH MIGRAINE
    Skljarevski, V.
    Oakes, T.
    Ferguson, M.
    Zhang, Q.
    Martinez, J.
    Johnson, K.
    Schacht, A.
    Due, M.
    Goadsby, P.
    Dodick, D.
    CEPHALALGIA, 2016, 36 : 42 - 42
  • [39] Efficacy and safety of LY2951742 in a randomized, double-blind, placebo-controlled, dose-ranging study in patients with migraine
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V
    Martinez, J. M.
    Johnson, K. W.
    Schacht, A. L.
    Due, M. R.
    Goadsby, P.
    Dodick, D. W.
    HEADACHE, 2016, 56 : 68 - 68
  • [40] GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus
    Levy, Cynthia
    Kendrick, Stuart
    Bowlus, Christopher L.
    Tanaka, Atsushi
    Jones, David
    Kremer, Andreas E.
    Mayo, Marlyn J.
    Haque, Nazneen
    von Maltzahn, Robyn
    Allinder, Matthew
    Swift, Brandon
    McLaughlin, Megan M.
    Hirschfield, Gideon M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1902 - +
12345